Race Oncology’s Dr Daniel Tillett chats FTO inhibitors
Race Oncology’s CEO Dr Daniel Tillett joins Fraser Palamara on Stockhead TV to talk about it’s recent collaboration with Monash University.
Stockhead
Asset manager backs two wagering plays
Australia’s love of betting is as strong as ever, although the wagering market is consolidating. One asset manager is tipping BlueBet and PointsBet to succeed.
Long Shortz with Singular Health Group
Singular Health Group has inked a major deal with the Miami-based Provider Network Solutions for its 3Dicom software.
WTF with Weebit Nano
Weebit Nano CEO Coby Hanoch gives Stockhead TV the skinny on a semiconductor industry with almost-unquantifiable influence.
More Stories
GT1 eyes new lithium zone
Mapping and sampling work at Green Technology Metals’ Junior lithium project is proving successful with identification of extensions to known mineralisation.
Institutions target gold juniors as value emerges
As prices ride to record highs, junior gold companies are floating onto the radar of institutional investors.
ASX Small Caps Lunch Wrap
The market has been moving slowly today, held back by big retailers and sliding commodities.
Investors hot for Lachlan Fold Belt copper
Golden Deeps goes meteoric, up 217% on copper, while other ASX juniors rise on the red metal today.
Break it Down: Conrad Energy Asia
Break it Down goes into on a Conrad Asia Energy (ASX:CRD) sales deal hailed as the most significant event in its history.
Top 10 at 11: Fresh from the ASX today
Good morning, and welcome to Stockhead’s Top 10 at 11, a short, sharp update to help frame the trading day.
PGD finds new gold prospect at Newman
Early exploration work at Peregrine Gold’s Newman project has led to the discovery of the Kangaroo prospect with stream sampling returning up to 4.9g/t gold.
Break it Down: Great Boulder Resources
Break it Down goes into a high-grade Great Boulder Resources gold strike north of a large established resource which bolstered expectations for an upgrade.
Noxopharm has difficult brain cancer in its sights
Preclinical work based on two novel drugs holds promise for one of the most difficult and fatal cancers.
Beonic accelerates growth with $5.5m raise
Beonic set to take its physical spaces data analytics tech to more international customers thanks to an oversubscribed $5 million placement and SPP.
Original URL: https://www.heraldsun.com.au/business/stockhead/page/200